| Company type | Public |
|---|---|
| Industry | |
| Founded | January 27, 2016 in Gothenburg, Sweden |
| Founders |
|
| Headquarters | , |
Area served | Worldwide |
Key people |
|
Number of employees | 100-150 (2019) |
| Website | www |
Cellink is a biotechnology startup that designs bio-inks and bioprinters for culturing different cell types. The company has ongoing collaborations with organizations including MedImmune, MIT and Takara Bio, and its printers are used for research at Harvard University, Merck, Novartis, the U.S. Army, Toyota, Johnson & Johnson and more.
History
editCellink was officially founded in 2016 by Erik Gatenholm and Héctor Martinez. They developed and sold the world's first universally compatible bio-ink to simplify bioprinting for academics and pharmaceutical companies who were, at that time, mixing their own biomaterial in-house.[1][2] The company released its first bioprinter to test the market in 2015, and continued designing additional bio-inks to support more specialized applications in bioprinting.[2]
Ten months after it was founded, Cellink was listed publicly on the Nasdaq.[3] At its IPO, shares were oversubscribed by 1070 percent.[3]
As of February 2019, the company's products are used by more than 600 labs in more than 50 countries.[4]
See also
editReferences
edit- ^ "The firm that can 3D print human body parts". BBC. 2017.
- ^ a b "Inside Cellink, the Swedish company building 3D printers for living tissue". Digital Trends. 2018.
- ^ a b "From nothing to a super-IPO in only 10 months - Cellink is making it possible to 3D-print human tissues and organs". Business Insider. 2016.
- ^ "CELLINK is creating ripples in growing bioprinting sector". MedicalExpo e-magazine. 2019.